[Design and expression of recombinant HER-2 antigen as a marker for detection of breast cancer]
Modares Journal of Medical Sciences, Pathobiology. 2015; 17 (4): 89-99
en Persa
| IMEMR
| ID: emr-185164
ABSTRACT
Objective:
The incidence of breast cancer is approximately one million which makes this cancer one of the most common among women worldwide. Breast cancer comprises 7% of the total death rate caused by cancers. Several strategies that use tumor-associated antigen [TAA] vaccination and early detection of breast cancer are clinically being developed. Breast cancer is caused by increased over expression of certain genes. HER-2 is a tyrosine kinase receptor in the epidermal growth factor family. The role of HER-2 in breast cancer has been extensively studied. HER-2 is found in 25%-30% of breast cancer patients. Herceptin, a human antibody, is used as a therapeutic target for HER-2. The purpose of this study is to produce recombinant protein HER-2 for early detection of breast cancer cells
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Tipo de estudio:
Estudio de tamizaje
Idioma:
Persa
Revista:
Modares J. Med. Sci., Pathobiol.
Año:
2015
Similares
MEDLINE
...
LILACS
LIS